DK1947093T3 - Substituerede morpholin og thiomorpholin derivater - Google Patents

Substituerede morpholin og thiomorpholin derivater

Info

Publication number
DK1947093T3
DK1947093T3 DK08007169.9T DK08007169T DK1947093T3 DK 1947093 T3 DK1947093 T3 DK 1947093T3 DK 08007169 T DK08007169 T DK 08007169T DK 1947093 T3 DK1947093 T3 DK 1947093T3
Authority
DK
Denmark
Prior art keywords
substituted morpholine
thiomorpholine derivatives
thiomorpholine
derivatives
morpholine
Prior art date
Application number
DK08007169.9T
Other languages
English (en)
Inventor
Mario Rottlaender
Nikolay Khanzhin
Andreas Ritzen
William Patrick Watson
Thornoee Christian Wenzel
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37730781&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1947093(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Application granted granted Critical
Publication of DK1947093T3 publication Critical patent/DK1947093T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
DK08007169.9T 2004-03-12 2005-03-09 Substituerede morpholin og thiomorpholin derivater DK1947093T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55257404P 2004-03-12 2004-03-12
DKPA200400412 2004-03-12
EP05706819A EP1727809B8 (en) 2004-03-12 2005-03-09 Substituted morpholine and thiomorpholine derivatives

Publications (1)

Publication Number Publication Date
DK1947093T3 true DK1947093T3 (da) 2010-02-01

Family

ID=37730781

Family Applications (2)

Application Number Title Priority Date Filing Date
DK08007169.9T DK1947093T3 (da) 2004-03-12 2005-03-09 Substituerede morpholin og thiomorpholin derivater
DK05706819T DK1727809T3 (da) 2004-03-12 2005-03-09 Substituerede morpholin og thiomorpholin derivater

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK05706819T DK1727809T3 (da) 2004-03-12 2005-03-09 Substituerede morpholin og thiomorpholin derivater

Country Status (32)

Country Link
US (6) US7501414B2 (da)
EP (3) EP1727809B8 (da)
JP (1) JP5006184B2 (da)
KR (2) KR101411204B1 (da)
CN (2) CN102516204B (da)
AR (1) AR049784A1 (da)
AT (2) ATE443702T1 (da)
AU (1) AU2005221762B2 (da)
BR (1) BRPI0508570B8 (da)
CA (1) CA2559397C (da)
CO (1) CO5721001A2 (da)
CY (2) CY1110392T1 (da)
DE (2) DE602005016849D1 (da)
DK (2) DK1947093T3 (da)
EA (1) EA015120B1 (da)
EG (1) EG25344A (da)
ES (2) ES2334076T3 (da)
HK (1) HK1172618A1 (da)
HR (1) HRP20090685T1 (da)
IL (1) IL177859A (da)
MY (2) MY147786A (da)
NO (1) NO337161B1 (da)
NZ (1) NZ549133A (da)
PL (2) PL1727809T3 (da)
PT (2) PT1727809E (da)
RS (2) RS51066B (da)
SG (1) SG151254A1 (da)
SI (2) SI1947093T1 (da)
TW (2) TWI357901B (da)
UA (2) UA102517C2 (da)
WO (1) WO2005087754A1 (da)
ZA (2) ZA200607286B (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799832B2 (en) 2003-10-23 2010-09-21 Valeant Pharmaceuticals North America Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
TWI357901B (en) 2004-03-12 2012-02-11 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivati
UA89503C2 (uk) 2004-09-13 2010-02-10 Х. Луннбек А/С Заміщені похідні аніліну
UA92340C2 (en) * 2005-03-03 2010-10-25 Х. Луннбек А/С Substituted pyridine derivatives
US7812020B2 (en) * 2005-03-03 2010-10-12 H. Lundbeck A/S Substituted pyridine derivatives
CN101378742B (zh) * 2006-02-07 2013-07-10 H.隆德贝克有限公司 Kcnq-开放剂在制备用于治疗精神分裂症的药物组合物中的用途
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
DK2061465T3 (da) 2006-08-23 2013-07-08 Valeant Pharmaceuticals Int Derivater af 4-(N-azacycloalkyl)anilider som kaliumkanalmodulatorer
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
MX2009005652A (es) 2006-11-28 2009-08-07 Valeant Pharmaceuticals Int Analogos 1,4 diamino biciclicos de retigabina como moduladores de canales de potasio.
WO2008130616A2 (en) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines as cb1 modulators
US8367684B2 (en) 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US20100256145A1 (en) * 2007-08-01 2010-10-07 H. Lundbeck A/S Use of kcnq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted
US7786146B2 (en) 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
EP2116618A1 (en) 2008-05-09 2009-11-11 Agency for Science, Technology And Research Diagnosis and treatment of Kawasaki disease
WO2010094645A1 (en) * 2009-02-17 2010-08-26 Neurosearch A/S Substituted pyridine derivatives and their medical use
WO2010094644A1 (en) * 2009-02-17 2010-08-26 Neurosearch A/S Substituted pyridine derivatives and their medical use
US20100286138A1 (en) * 2009-05-11 2010-11-11 H. Lundbeck A/S Stable forms of N-(2,6-Dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide
TW201041857A (en) * 2009-05-11 2010-12-01 Lundbeck & Co As H Stable forms of N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide
US20120232058A1 (en) * 2009-09-07 2012-09-13 Neurosearch A/S Substituted pyridine derivatives and their medical use
WO2012004698A1 (en) 2010-07-08 2012-01-12 Pfizer Inc. Piperidinyl pyrimidine amides as kv7 potassium channel openers
CN103073455B (zh) 2011-10-25 2015-08-19 中国科学院上海药物研究所 一类新型的kcnq钾通道激动剂、其制备方法和用途
US9321750B2 (en) * 2012-04-20 2016-04-26 Innov17 Llc ROR modulators and their uses
CN103044431A (zh) * 2012-10-22 2013-04-17 中国药科大学 制备五氟磺草胺的新方法
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
WO2016090317A1 (en) * 2014-12-05 2016-06-09 Aquinnah Pharmaceuticals, Inc. Sulfonamide derivatives, compositions and methods of use in the treatment of neurodegenerative diseases
EP3366683A1 (en) 2017-02-28 2018-08-29 Acousia Therapeutics GmbH Cyclic amides, acteamides and ureas useful as potassium channel openers
EP3917907A1 (en) 2019-01-29 2021-12-08 Universitá Degli Studi Di Salerno Modulators of potassium ion channels and uses thereof
IL282188A (en) * 2021-04-08 2022-11-01 Yeda Res & Dev Combined use of ketamine and bretigabine for the treatment of psychiatric disorders

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03175086A (ja) * 1989-09-14 1991-07-30 Fuji Photo Film Co Ltd ジアゾ感熱記録材料
DE4200259A1 (de) 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
DE19539861A1 (de) 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
NZ329200A (en) * 1996-12-16 1999-05-28 Hoechst Ag Sulphonamide substituted quinazoline, isoquinoline, quinoline or benzo[1,3-]oxazine derivatives and medicaments
AU6645998A (en) * 1996-12-23 1998-07-17 Du Pont Pharmaceuticals Company Oxygen or sulfur containing heteroaromatics as factor xa inhibitors
CA2275796A1 (en) * 1996-12-23 1998-07-02 Donald Joseph Phillip Pinto Nitrogen containing heteroaromatics as factor xa inhibitors
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
US6187797B1 (en) * 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
JP2001526268A (ja) * 1997-12-22 2001-12-18 デュポン ファーマシューティカルズ カンパニー Ｘａ因子阻害剤としての、オルト−置換Ｐ１を有する、窒素含有複素環式芳香族化合物
ATE278673T1 (de) 1998-03-27 2004-10-15 Bristol Myers Squibb Pharma Co Disubstituierte pyrazoline und triazoline als faktor xa inhibitoren
NZ516743A (en) * 1999-08-04 2004-02-27 Icagen Inc Methods for treating or preventing pain and anxiety
US6495550B2 (en) * 1999-08-04 2002-12-17 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
US6117900A (en) 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
JP2003534801A (ja) 2000-05-26 2003-11-25 ブリストル−マイヤーズ スクイブ カンパニー ヒトｋｃｎｑ５カリウムチャンネル、並びにその方法および組成物
AU2001268303A1 (en) 2000-06-11 2001-12-24 Du Pont Pharmaceuticals Company Hepatitis c protease exosite for inhibitor design
PE20020044A1 (es) * 2000-06-16 2002-01-30 Upjohn Co Tiazina oxazolidinona
US6589986B2 (en) * 2000-12-20 2003-07-08 Wyeth Methods of treating anxiety disorders
AU2002225551B8 (en) * 2001-01-16 2008-05-29 Astrazeneca Ab Therapeutic chroman compounds
MXPA03006268A (es) * 2001-01-16 2003-09-22 Astrazeneca Ab Compuestos terapeuticos de cromano.
CN1250519C (zh) * 2001-01-19 2006-04-12 中国人民解放军军事医学科学院毒物药物研究所 具有调节钾通道功能的胺衍生物及其制备方法和应用
EP1361879A1 (en) * 2001-02-20 2003-11-19 Bristol-Myers Squibb Company 2,4-disubstituted pyrimidine-5-carboxamide derivatives as kcnq potassium channel modulators
SE0103649D0 (sv) * 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinoline compounds
SE0103648D0 (sv) * 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinolone compounds
TWI357901B (en) * 2004-03-12 2012-02-11 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivati

Also Published As

Publication number Publication date
MY147786A (en) 2013-01-31
PL1947093T3 (pl) 2010-02-26
JP2007528880A (ja) 2007-10-18
CA2559397C (en) 2010-08-10
NZ549133A (en) 2010-09-30
EP1727809B1 (en) 2008-06-11
TWI357901B (en) 2012-02-11
EP1727809B8 (en) 2008-10-29
CA2559397A1 (en) 2005-09-22
EP1727809A1 (en) 2006-12-06
RS51066B (sr) 2010-10-31
AU2005221762A1 (en) 2005-09-22
DE602005007474D1 (en) 2008-07-24
TWI349666B (en) 2011-10-01
TW200811121A (en) 2008-03-01
US20100063033A1 (en) 2010-03-11
US20100063036A1 (en) 2010-03-11
ES2334076T3 (es) 2010-03-04
CN102516204A (zh) 2012-06-27
ES2306087T3 (es) 2008-11-01
ATE398112T1 (de) 2008-07-15
US20060167248A1 (en) 2006-07-27
WO2005087754A1 (en) 2005-09-22
RS50606B (sr) 2010-05-07
KR20120136422A (ko) 2012-12-18
US8012962B2 (en) 2011-09-06
IL177859A (en) 2013-02-28
CN1930138A (zh) 2007-03-14
EP1947093A1 (en) 2008-07-23
CY1109656T1 (el) 2014-08-13
PT1727809E (pt) 2008-08-13
SI1727809T1 (sl) 2008-10-31
SG151254A1 (en) 2009-04-30
AR049784A1 (es) 2006-09-06
KR101411204B1 (ko) 2014-06-23
ZA200709718B (en) 2008-09-25
CO5721001A2 (es) 2007-01-31
US8299075B2 (en) 2012-10-30
US20110294787A1 (en) 2011-12-01
HK1172618A1 (zh) 2013-04-26
ATE443702T1 (de) 2009-10-15
EG25344A (en) 2011-12-14
UA90670C2 (en) 2010-05-25
EA200601686A1 (ru) 2007-02-27
BRPI0508570A (pt) 2007-08-14
TW200533359A (en) 2005-10-16
CY1110392T1 (el) 2015-04-29
NO20064599L (no) 2006-12-08
US7501414B2 (en) 2009-03-10
ZA200607286B (en) 2008-04-30
BRPI0508570B8 (pt) 2021-05-25
CN102516204B (zh) 2016-01-20
US20090143369A1 (en) 2009-06-04
BRPI0508570B1 (pt) 2018-11-21
EP2138487A1 (en) 2009-12-30
US7812023B2 (en) 2010-10-12
HRP20090685T1 (hr) 2010-02-28
DK1727809T3 (da) 2008-09-29
JP5006184B2 (ja) 2012-08-22
US20090137571A1 (en) 2009-05-28
EP1947093B9 (en) 2010-03-03
US7632835B2 (en) 2009-12-15
IL177859A0 (en) 2006-12-31
EP1947093B1 (en) 2009-09-23
EA015120B1 (ru) 2011-06-30
PT1947093E (pt) 2009-12-22
NO337161B1 (no) 2016-02-01
UA102517C2 (ru) 2013-07-25
MY143698A (en) 2011-06-30
KR20060128004A (ko) 2006-12-13
DE602005016849D1 (de) 2009-11-05
SI1947093T1 (sl) 2010-01-29
PL1727809T3 (pl) 2008-11-28
AU2005221762B2 (en) 2011-06-09

Similar Documents

Publication Publication Date Title
DK1727809T3 (da) Substituerede morpholin og thiomorpholin derivater
CY2015036I2 (el) Νεα παραγωγα οξαζολιδινονης
NO20053974D0 (no) Tienopyrimidinforbindelser og anvendelse derav.
DK1594840T3 (da) Piperidin-benzensulfonamid-derivater
IS8180A (is) Nýjar besímídasólafleiður
NO20054136D0 (no) Imidazol-4-yl-etynyl-pyridin-derivater
ATE420066T1 (de) Amidoacetonitrilderivate
ATE352550T1 (de) Chinazolinderivate
DK1771421T3 (da) N-hydroxyamidderivater og anvendelse deraf
NO20054135D0 (no) Kipolinon/benzoksazin derivater og anvendelser derav
DK1885716T3 (da) Thiazolderivater og anvendelse deraf
DK1603915T3 (da) Substituerede 8-pyridinyl-dihydrospiro-cycloalkyl-pyrimido- 1,2-a-pyrimidin-6-on og 8-pyrimidinyl-dihydrospiro-cycloalkyl-pyrimido-1,2-a-pyrimidin-6-on-derivater og deres anvendelse mod neurogenerative sygdomme
IS7980A (is) Díarýlmetýlídenpíperidínafleiður, framleiðsla þeirra og notkun
IS8045A (is) Púrín-6-ón-afleiður
DE50308254D1 (de) Messgerät
DE602004013236D1 (de) Messgerät
DK1682129T3 (da) N-thiazol-2-ylbenzamidderivater
DK1706373T3 (da) Amidoacetonitrilderivater
DK1658592T3 (da) Skriver og en skrivers funktion
DE502005001764D1 (de) Erweiterbares Steuergerät
DE602004008130D1 (de) Messuhr
DK1631229T3 (da) Oppustelig pude
DE10349030B4 (de) Axialverstellvorrichtung
DE602006020043D1 (de) Expandierbares bandscheibenimplantat
AT6960U3 (de) Spülkasten